基于国家和首都在提升重大心血管疾病临床防治水平方面的迫切需求，本实验室于2014年正式成立。本实验室针对急性心肌梗死这一日趋严峻的公共卫生问题，紧密围绕亟待解决的两大关键临床问题：（1）缺乏心肌坏死之前的早期预警手段，（2）临床实践与指南要求存在很大差距。旨在构建创新型、规范化和普适性的急性心肌梗死早期预警与干预模式，为提高首都乃至全国急性心肌梗死的整体防控水平与质量做出贡献。

　　急性心肌梗死（AMI）是目前全球致死率最高的心血管疾病，也是引起猝死最主要的原因。我国的AMI防治形势尤为严峻，患病率持续增长，死亡率居高不下，其关键原因是缺乏心肌坏死之前的早期预警手段以及临床实践与指南要求存在很大差距。针对上述问题，开展如下研究：1、AMI早期预警体系建立：在“治未病”理念指导下，从生物标志物、心电学、影像学和遗传学方面入手，研发早期预警AMI的新型指标，并验证在临床实践中指导早期诊疗的价值；2、AMI干预模式优化：根据医学指南要求，对AMI的临床实践实施医疗质量改进，开展早期救治的T3转化阶段研究和患者疾病管理的“智慧医疗”模式探索，以优化当前AMI的防治模式。

　　本实验室目前共有固定人员46名，其中研究人员39名，技术人员7名（含兼任）；研究人员中有正高级职称17人，副高级职称12人；博士生导师7人，硕士生导师11人；具有博士学位40人。技术人员中副高及以上职称2人，博士学位2人。

　　拥有临床（心导管/电生理/心脏超声/心电图）、基础（细胞生物学/分子生物学/遗传学/病理学/小动物心血管功能评价）和转化医学（临床标本库/随访系统）三大平台。

　　于2017年分别荣获《华夏医疗保健国际交流促进科技奖》三等奖、《中华预防医学会科学技术奖》三等奖和《中国康复医学会科学技术奖科学技术进步奖》二等奖，共3项科技奖励。

　　本实验室围绕急性心肌梗死这一严重危害人类健康的重大心血管疾病，针对造成其严重疾病负担的主要原因-早期预警手段缺乏与医学指南和临床实践之间存在鸿沟，重点开展如下两方面研究：1、早期预警体系建立：在生物信息学、高通量测序、大数据分析、结构与功能影像学等新型科学研究手段不断出现的大背景下，从生物标志物、心电学、影像学和遗传学四大方面，发现和正在验证数个可以早期预警急性心肌梗死发生的指标；同时，明确早期预警的生物标志物、遗传指标在急性心肌梗死发生中的作用机理，提出急性心肌梗死新型防治靶点。2、干预模式优化：开展急性心肌梗死早期救治的T3转化阶段研究，明确急性心肌梗死患者早期再灌注治疗的延迟环节，开展优化改进工作，并初步建立和完善了12导联心电图和关键临床信息的院前-院内传输系统以及院前早期诊断流程与处理方案，提高急性心肌梗死的医疗服务水平和质量。

　　共发表学术论文共38篇，其中SCI论文21篇。申请国家发明专利及实用新型专利共9项，参加国际心血管学术大会交流发言共40余人次。

 

　　机构负责人：陈红

　　联系人：宋俊贤

　　邮箱：sjx221@163.com

　　电话：13426191391

　　地址：北京市西城区西直门南大街11号

 

　　Beijing Key Laboratory of Early Prediction and Intervention of Acute Myocardial Infarction

　　Based on the urgent needs of China and the capital to improve the clinical prevention and treatment of major cardiovascular diseases, our laboratory was officially established in 2014. To solve the increasingly serious public health problems of acute myocardial infarction, the laboratory mainly focuses on two critical clinical issues that need to be resolved urgently: (1) lack of early prediction methods before myocardial necrosis, (2) a big gap between clinical practice and guidelines. The purpose of the laboratory is to build an innovative, standardized and universal early prediction and intervention model for acute myocardial infarction, so as to contribute to the improvement of the overall prevention and control of acute myocardial infarction in the capital and even the whole country.

　　Acute myocardial infarction (AMI) is currently the most deadly cardiovascular disease in the world and is also the leading cause of sudden death. Nowadays the situation of AMI prevention and control in China is particularly severe. The prevalence rate continues to increase and the mortality rate remains high. And the key reasons are the lack of early prediction methods before myocardial necrosis, and the big gap between clinical practice and guidelines. In response to the above issues, the following studies were carried out: 1. The establishment of an early prediction system for AMI: Under the guidance of the concept of "Preventive treatment of diseases", starting with biomarkers, electrocardiography, imaging, and genetics, we developed new biomarkers for early prediction of AMI and verified their value of guiding early diagnosis and treatment in clinical practice. 2. The optimizing the AMI intervention model: According to the requirements of medical guidelines, the laboratory carried out T3 transformation phase research of early treatment and explored the “smart medical treatment” model of patient disease management to implement medical quality improvement in the clinical practice of AMI, so as to optimize the current AMI prevention and treatment model.

　　The laboratory currently has a total of 46 permanent staff, including 39 researchers and 7 technical staff (including part-time staff). Among the research staff, there are 17 senior professional titles and 12 associate senior professional titles; 7 doctoral supervisors and 11 master supervisors; 40 doctoral degrees. Besides, among the technicians, there are 2 persons with senior or associate professional titles, and 2  with doctoral degrees. At the same time, the laboratory has three platforms including clinical platform (cardiac catheter/electrophysiology/cardiac ultrasound/electrocardiogram), basic medicine platform (cell biology/molecular biology/genetics/pathology/ assessment of small animal cardiovascular function) and translational medicine platform (clinical library/follow-up system).

　　In 2017, we won 3 science and technology awards, including the third prize of “Huaxia Healthcare International Communicational Promotion Technology Award”, the third prize of “Chinese Preventive Medicine Association Science and Technology Award” and the second prize of “China Association of Rehabilitation Medicine Science and Technology Award”.

　　The laboratory focuses on acute myocardial infarction, a major cardiovascular disease that seriously harms human health. And in order to solve the main reason of this severe disease burden——the lack of early prediction methods before myocardial necrosis, and the big gap between clinical practice and guidelines，we focus on the following two aspects: 1. Establishment of early prediction system: In the background of the continuous emergence of new science research technology, likebioinformatics, high-throughput sequencing, big data analysis, structural and functional imaging, we found and are validating several biomarkers of the early prediction of the occurrence of acute myocardial infarction from four aspects of biomarkers, electrocardiography, imaging and genetics. At the same time, the mechanism of early prediction biomarkers and genetic indicators in the occurrence of acute myocardial infarction was defined, and a new target of the prevention and treatment of acute myocardial infarction was proposed. 2. Optimization of intervention model: The study of T3 transformation phase of early treatment of acute myocardial infarction was conducted to identify the delays in the early reperfusion treatment of AMI patients. And optimization and improvement work was carried out. A 12-lead ECG，the pre-hospital-hospital transmission system of key clinical information，pre-hospital early diagnosis procedures and treatment plans were initially established and improved so that the level and quality of medical services for acute myocardial infarction can be improved.

　　A total of 38 academic papers have been published, including 21 SCI papers. A total of 9 national invention patents and utility model patents have been applied for, and the communicational speech in international cardiovascular academic conference are more than 40 person-times.

　　Lab manager: Chen Hong

　　Contact person: Song Junxian

　　E-mail:sjx221@163.com

　　Phone: 13426191391

　　Address: No. 11 Xizhimen South Street, Xicheng District, Beijing.